Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2019, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.
Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 4 and 2 respectively.
Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Degenerative Disc Disease - Overview
Degenerative Disc Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Degenerative Disc Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Degenerative Disc Disease - Companies Involved in Therapeutics Development
AnGes Inc
BioRestorative Therapies Inc
Bone Therapeutics SA
DiscGenics Inc
Kolon TissueGene Inc
Samumed LLC
U.S. Stem Cell Inc
Degenerative Disc Disease - Drug Profiles
AdipoCell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BRTX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CybroCell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTG-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-04690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-0002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Degenerative Disc Disease - Dormant Projects
Degenerative Disc Disease - Product Development Milestones
Featured News & Press Releases
Jan 07, 2019: DiscGenics announces that cell therapy IDCT has passed the initial safety review of its frirst-in-human clinical trial for degenerative disc disease
Dec 11, 2018: DiscGenics Receives Approval from Japanese Pharmaceuticals and Medical Devices Agency to Begin Clinical Evaluation of Non-Surgical Degenerative Disc Disease Treatment in Japan
Nov 14, 2018: Therapeutic potential of NTG-101, a single dose injectable treatment for Degenerative Disc Disease, demonstrated in preclinical large animal study published in Nature Publishing Group's "Scientific Reports"
Oct 18, 2018: BioRestorative Therapies announces the appointment of Lance Alstodt as executive VP and chief strategy officer
Aug 15, 2018: Biorestorative Therapies announces publication of study results validating the benefits of using hypoxic cultured cells to treat patients with degenerative disc disease
Jun 11, 2018: BioRestorative Therapies Reports Positive Findings from Independent Review of its BRTX-100 Program
May 31, 2018: Samumed to Present Data on SM04690 at The Orthobiologic Institute (TOBI) 2018 Annual Symposium
May 30, 2018: DiscGenics: New Cell Therapy Could Help Millions Suffering from Back Pain
May 07, 2018: BioRestorative Therapies Appoints Wayne J. Olan as Clinical Director of Regenerative Disc/Spine Program
May 03, 2018: CTI Clinical Trial and Consulting Services Announces Collaboration with DiscGenics on First-In-Human Trial of Cell Therapy IDCT for Degenerative Disc Disease
Apr 26, 2018: DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease
Mar 22, 2018: DiscGenics Presents Promising Preclinical Study Results at ORS 2018
Mar 20, 2018: USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas
Feb 28, 2018: USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference
Feb 15, 2018: Cryoport to Provide DiscGenics with Cutting Edge Cold Chain Logistics Support for its Phase 1/2 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Degenerative Disc Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Degenerative Disc Disease - Pipeline by AnGes Inc, H1 2019
Degenerative Disc Disease - Pipeline by BioRestorative Therapies Inc, H1 2019
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2019
Degenerative Disc Disease - Pipeline by DiscGenics Inc, H1 2019
Degenerative Disc Disease - Pipeline by Kolon TissueGene Inc, H1 2019
Degenerative Disc Disease - Pipeline by Samumed LLC, H1 2019
Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H1 2019
Degenerative Disc Disease - Dormant Projects, H1 2019
List of Figures
Number of Products under Development for Degenerative Disc Disease, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
